Resistell News:

Nature Communications publishes Resistell's groundbreaking AST platform

Nature Communications publishes Resistell's groundbreaking AST platform
Resistell News:

Nature Communications publishes Resistell's groundbreaking AST platform

Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).

More
Nature Communications publishes Resistell's groundbreaking AST platform

Latest news

Please join us in welcoming Trevor Hawkins to our Board of Directors at Resistell!
4th March 2024

Please join us in welcoming Trevor Hawkins to our Board of Directors at Resistell!

With a remarkable 25-year journey at the forefront of healthcare innovation, Trevor brings a wealth of experience from his leadership roles across research, clinical, and corporate spheres globally. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to our team. Welcome aboard, Trevor!
More
Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project
4th March 2024

Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project

Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project to build Phenotech-CF, a workflow that will reshape how antimicrobials are delivered to patients suffering from cystic fibrosis.
More
Watch our webcast with Nature on Nanomotion Technology for Ultrarapid Antibiotic Susceptibility Testing
5th February 2024

Watch our webcast with Nature on Nanomotion Technology for Ultrarapid Antibiotic Susceptibility Testing

Our latest webcast with Nature is now available for replay. Join us as we delve into the science behind nanomotion technology and its application in real-world healthcare settings. Learn about Resistell’s groundbreaking technology platform that leverages the power of nanomotion technology to transform the fight against antibiotic resistance.
More
Resistell among TOP 10 best start-ups 2023 in Switzerland
7th September 2023

Resistell among TOP 10 best start-ups 2023 in Switzerland

[TOP 100 Swiss Startup Award](https://www.top100startups.swiss/) has become a benchmark in Switzerland’s startup ecosystem. The award show connects the most promising Swiss startups with Swiss and international investors, executives, and journalists. The invitation-only Award Night has become the most awaited start-up event of the year. We are honored to announce that Resistell has once again secured a coveted spot in the Top 10 of the TOP 100 Swiss Startup Award! For the third time, our dedication to innovation has been recognized by a panel of 100 leading investors and industry experts. This prestigious award is not just a recognition of our hard work, but also a testament to the incredible team behind Resistell and the invaluable support from our partners and stakeholders. We are thrilled to be part of Switzerland’s dynamic startup ecosystem, and we remain committed to pushing the boundaries of science and technology to combat antibiotic resistance and improve patient care.
More